| Literature DB >> 11801694 |
Hans J J van der Vliet1, B Mary E von Blomberg, Mette D Hazenberg, Nobusuke Nishi, Sigrid A Otto, Birgit H van Benthem, Maria Prins, Frans A Claessen, Alfons J M van den Eertwegh, Giuseppe Giaccone, Frank Miedema, Rik J Scheper, Herbert M Pinedo.
Abstract
CD1d-restricted NKT cells express an invariant TCR and have been demonstrated to play an important regulatory role in a variety of immune responses. Invariant NKT cells down-regulate autoimmune responses by production of type 2 cytokines and can initiate antitumor and antimicrobial immune responses by production of type 1 cytokines. Although defects in the (invariant) Valpha24+Vbeta11+ NKT cell population have been observed in patients with cancer and autoimmune diseases, little is known regarding the protective role of Valpha24+Vbeta11+ NKT cells in human infectious disease. In a cross-sectional study in HIV-1-infected individuals, we found circulating numbers of Valpha24+Vbeta11+ NKT cells to be reduced, independent of CD4+ T cell counts, CD4:CD8 ratios, and viral load. Because a small minority of Valpha24+Vbeta11+ NKT cells of healthy donors expressed HIV-1 (co)receptors and the vast majority of Valpha24+Vbeta11+ NKT cells in HIV-1-infected individuals expressed the Fas receptor, the depletion was more likely due to Fas-mediated apoptosis than to preferential infection of Valpha24+Vbeta11+ NKT cells by HIV-1. A longitudinal cohort study, in which patients were analyzed before seroconversion and 1 and 5 years after seroconversion, demonstrated that a large proportion of the depletion occurred within the first year postseroconversion. In this longitudinal study no evidence was found to support an important role of Valpha24+Vbeta11+ NKT cells in determining the rate of progression during HIV-1 infection.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11801694 DOI: 10.4049/jimmunol.168.3.1490
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422